Virchow Medical, Inc., a company advancing biopsy specimen stewardship to expand access to precision oncology, today announced three milestones that strengthen its scientific leadership and accelerate its innovation roadmap. The first milestone is William Morice II, MD, PhD, President and Chief Executive Officer of Mayo Clinic Laboratories, has joined the Virchow Medical Scientific Advisory Board (SAB). In addition, Khosrow Shotorbani, Chief Executive Officer of Project Santa Fe Foundation and Founder of Clinical Lab 2.0, has transitioned from the Company’s Market Outreach Advisory Board to the Scientific Advisory Board, joining Dr. Morice and other SAB members.

Virchow Medical also recently convened its annual in-person SAB meeting at the Company’s headquarters in San Diego. The four-hour working session brought together leading experts in pathology, oncology, and laboratory medicine and resulted in several new, high-impact initiatives for the company’s product development pipeline.

“We are honored to welcome Dr. Morice to our Scientific Advisory Board and to have Khosrow Shotorbani transition to the SAB,” said Alexander Arrow, MD, Chief Executive Officer of Virchow Medical. “Their combined leadership across clinical laboratories, precision medicine, and healthcare delivery is invaluable as we continue to develop technologies that help more cancer patients benefit from genomic testing and therefore from precision medicine. Our recent SAB session was the most productive we’ve held. The input we received from our SAB members is already shaping the next phase of our innovation strategy.”

Dr. Morice is a nationally recognized leader in laboratory medicine and pathology. He served as the chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic from 2015 to 2022 and held the same role in the Division of Hematopathology from 2009 to 2015. Dr. Morice is also a professor of laboratory medicine and pathology at Mayo Clinic College of Medicine and Science, and has published over 160 peer-reviewed articles and book chapters. He joined the Virchow Medical SAB last month.

Mr. Shotorbani is widely known for his leadership in value-based laboratory medicine, longitudinal data, and his work founding and advancing the Clinical Lab 2.0 movement. He has already been advising Virchow on the company’s Market Outreach Advisory Board, and is now switching to the more scientifically focused Scientific Advisory Board. He previously served as CEO of TriCore Reference Laboratories, one of the top 20 clinical reference labs in the United States, and is an ASCP board certified laboratory scientist.

“The Crow’s Nest is simplicity, yet it’s ingenuity. It’s an incredible step solving an old, old problem with a new way of thinking,” said Khosrow Shortorbani. “Expanding access to actionable diagnostic information is central to improving outcomes. This is how you bring the pieces of the puzzle together, add value for us in diagnostics, help patients and hurt them less in the process. I am blown away with the concept and I continue to be enamored of it.”

“Our Scientific Advisory Board plays a critical role in helping us prioritize and refine our early-stage pipeline,” said Wilfrido Mojica, MD, Chief Technology Officer of Virchow Medical. “Their guidance ensures that we are not only pursuing technically innovative concepts, but also focusing on solutions that are clinically meaningful and aligned with the real-world needs of oncologists, interventional radiologists, pathologists, and patients.”

About Virchow Medical, Inc.

Virchow’s mission is to unlock critical molecular data for every cancer patient and enable precision medicine to save more lives. It does this by providing its hospital subscribers with a monthly supply of Crow’s Nest® Biopsy Catchment® System units, which are used after core needle tumor biopsies to create Virchow Companion Specimens (VCSs). The company stores the VCSs for its customers in a unique biorepository, the Virchow Vault,^TM housed in a CAP-accredited facility. As a result, oncologists can log on to www.virchowvault.com at any time after their patient’s biopsy and order genomic sequencing or other molecular testing without requesting their hospital’s pathology department to provide any of the tissue block. In an era which Formalin-Fixed Paraffin-Embedded (FFPE) tissue is limited and often insufficient, this ability to order sequencing using only high-quality material that is normally discarded on used needles is designed to provide every biopsy patient the potential opportunity to be treated with precision medicine targeted therapy.

For further information, visit www.virchowmed.com, and follow Virchow on LinkedIn at https://www.linkedin.com/company/virchowmed/.

Virchow Medical is an EvoNexus portfolio company.

Crow’s Nest®, Virchow Vault^TM, Biopsy Catchment®, Precision Can’t Waste^TM, and Virchow Companion Specimen^TM are trademarks of Virchow Medical, Inc.